Approval · Notice of Compliance 21486 · 2018
JANUVIA: Notice of Compliance 21486
Issued November 2, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21486
- Date
- November 2, 2018
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the product monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JANUVIA | Not yet assigned | — |
Medicinal ingredients
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 25 MG per TAB
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 50 MG per TAB
- SITAGLIPTIN PHOSPHATE MONOHYDRATE 100 MG per TAB